Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × repaglinide × 1 year × Clear all
NCT05384626 2026-05-27

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Nuvalent Inc.

Phase 1/2 Recruiting
840 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡